Precision medicine in cancer: challenges and recommendations from an EU-funded cervical cancer biobanking study
暂无分享,去创建一个
Philippe Hupé | Leanne de Koning | Marina Popovic | Maud Kamal | Balazs Balint | E. Berns | G. Kenter | P. Hupé | B. Bálint | M. Kamal | H. E. von der Leyen | E. Jordanova | L. de Koning | Ksenia Bagrintseva | Choumouss Kamoun | Sanne Samuels | Heiko von der Leyen | Ekaterina S Jordanova | Gemma G Kenter | S. Scholl | S. Samuels | Choumouss Kamoun | Windy Luscap-Rondof | U. Wittkop | Ksenia Bagrintseva | M. Popovic | Atttila Kereszt | Windy Luscap-Rondof | Ulrike Wittkop | Atttila Kereszt | Els Berns | Susy Scholl
[1] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[2] F. Guadagni,et al. Ensuring Sample Quality for Biomarker Discovery Studies - Use of ICT Tools to Trace Biosample Life-cycle. , 2015, Cancer genomics & proteomics.
[3] M. Choti,et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.
[4] Amy L. Powers,et al. Cancer patient perceptions about biobanking and preferred timing of consent. , 2014, Biopreservation and biobanking.
[5] W. Cho,et al. Circulating tumor DNA: new horizons for improving cancer treatment. , 2015, Future oncology.
[6] O. Peralta-Zaragoza,et al. Human papilloma virus, DNA methylation and microRNA expression in cervical cancer (Review) , 2014, Oncology reports.
[7] E. Jordanova,et al. Precise Classification of Cervical Carcinomas Combined with Somatic Mutation Profiling Contributes to Predicting Disease Outcome , 2015, PloS one.
[8] M Hummel,et al. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance , 2015, Cancer Gene Therapy.
[9] Gary D Bader,et al. International network of cancer genome projects , 2010, Nature.
[10] P. Grigsby,et al. Pathway-Specific Analysis of Gene Expression Data Identifies the PI3K/Akt Pathway as a Novel Therapeutic Target in Cervical Cancer , 2012, Clinical Cancer Research.
[11] Roman Rouzier,et al. Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials , 2015, Journal of the National Cancer Institute.
[12] Emmanuel Barillot,et al. Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial , 2014, Front. Genet..
[13] Bernard A. Fox,et al. Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma , 2015, Journal of Immunotherapy for Cancer.
[14] G. Batist,et al. Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine , 2013, Modern Pathology.
[15] Richard B. Schwab,et al. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay , 2016, Oncotarget.
[16] K. Kinzler,et al. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas , 2015, Science Translational Medicine.
[17] Vinay Prasad,et al. Perspective: The precision-oncology illusion , 2016, Nature.
[18] Roman Rouzier,et al. From prospective biobanking to precision medicine: BIO-RAIDs – an EU study protocol in cervical cancer , 2015, BMC Cancer.
[19] Bert Vogelstein,et al. DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .
[20] M. Erlander,et al. BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease , 2014, Oncotarget.
[21] Nicolas Servant,et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. , 2015, The Lancet. Oncology.
[22] Jill P Mesirov,et al. Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration , 2013, BMC Medicine.
[23] Arul M Chinnaiyan,et al. Translating genomics for precision cancer medicine. , 2014, Annual review of genomics and human genetics.
[24] N. Wages,et al. Cervical Cancer in Women Aged 35 Years and Younger. , 2016, Clinical therapeutics.
[25] K. Polyak,et al. Intra-tumour heterogeneity: a looking glass for cancer? , 2012, Nature Reviews Cancer.
[26] Carol Isaacson Barash,et al. tranSMART Foundation Datathon 1.0: The cross neurodegenerative diseases challenge , 2015, Applied & translational genomics.
[27] Trevor J Pugh,et al. Landscape of genomic alterations in cervical carcinomas , 2013, Nature.
[28] J. Miró,et al. COMPUTATIONAL SYSTEMS BIOLOGY OF CANCER , 2014 .
[29] M. Furue,et al. Melanoma therapy: Check the checkpoints , 2016, The Journal of dermatology.
[30] Richard Simon,et al. Implementing personalized cancer genomics in clinical trials , 2013, Nature Reviews Drug Discovery.
[31] P. Hammerman,et al. Genomic Landscape of Human Papillomavirus–Associated Cancers , 2015, Clinical Cancer Research.
[32] James Java,et al. Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] J. Messenger,et al. The National Cardiovascular Data Registry (NCDR) Data Quality Brief: the NCDR Data Quality Program in 2012. , 2012, Journal of the American College of Cardiology.
[34] Wei Huang,et al. A Colorful Future for Quantitative Pathology: Validation of Vectra Technology Using Chromogenic Multiplexed Immunohistochemistry and Prostate Tissue Microarrays , 2012 .
[35] C. Cui,et al. Chemotherapy, biochemotherapy and anti-VEGF therapy in metastatic mucosal melanoma. , 2014, Chinese clinical oncology.
[36] Vladimir Vacic,et al. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. , 2015, JAMA oncology.
[37] S. Takayama,et al. Recent developments in multiplexing techniques for immunohistochemistry , 2015, Expert review of molecular diagnostics.
[38] B. Monk,et al. Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials. , 2007, Gynecologic oncology.
[39] N. Tunariu,et al. Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration , 2015, Clinical Cancer Research.
[40] C. Paweletz,et al. Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA , 2014, Clinical Cancer Research.
[41] C. Swanton. Intratumor heterogeneity: evolution through space and time. , 2012, Cancer research.
[42] I. Bièche,et al. Circulating tumor DNA as a non‐invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types , 2015, Molecular oncology.
[43] Nicolai J. Birkbak,et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.
[44] K. Pantel,et al. Challenges in circulating tumour cell research , 2014, Nature Reviews Cancer.
[45] R. Sallam. Proteomics in Cancer Biomarkers Discovery: Challenges and Applications , 2015, Disease markers.